In the news
Feb. 18, 2021
An article published on GenomeWeb in December explored how the increased molecular testing capacity that labs throughout the U.S. built over the last year might be used once the COVID-19 pandemic is over.
Jane Hermansen, manager of Mayo Clinic Laboratories Outreach and Network Development, was one of the experts consulted. She noted that, even when demand for COVID-19 testing recedes, labs aren't likely to abandon the investment they put into molecular testing infrastructure.
"Hospital labs, pathology labs that have never even thought of being molecular laboratories in the past now have the equipment, and the equipment is easy enough to run that you don't have to have all the special capabilities you needed in the old days to actually have a molecular test menu," Hermansen says.
And while the long-term future may be up in the air, the article went on to note that demand for COVID-19 testing continues to remain high — meaning decisions about how to use excess molecular testing equipment post-pandemic won't be a pressing concern for some time to come.